Volume 18, Issue 3, Pages (September 2015)

Slides:



Advertisements
Similar presentations
The Path Forward for HIV-1 Vaccine Development
Advertisements

A View to a Kill: The Bacterial Type VI Secretion System Brian T. Ho, Tao G. Dong, John J. Mekalanos Cell Host & Microbe Volume 15, Issue 1, Pages 9-21.
Structural analysis of the unmutated ancestor of the HIV-1 envelope V2 region antibody CH58 isolated from an RV144 vaccine efficacy trial vaccinee Nathan.
Cell-to-Cell Transfer of M. tuberculosis Antigens Optimizes CD4 T Cell Priming Smita Srivastava, Joel D. Ernst Cell Host & Microbe Volume 15, Issue 6,
Volume 21, Issue 1, Pages (October 2017)
Volume 156, Issue 4, Pages (February 2014)
Peter D. Kwong, John R. Mascola  Immunity 
M. Juliana McElrath, Barton F. Haynes  Immunity 
Volume 21, Issue 1, Pages (October 2017)
Volume 24, Issue 5, Pages (May 2016)
Volume 14, Issue 5, Pages (November 2013)
Volume 165, Issue 7, Pages (June 2016)
Volume 38, Issue 1, Pages (January 2013)
HIV Immunology Goes Out On a Limb
Volume 16, Issue 1, Pages (July 2014)
Volume 22, Issue 5, Pages (November 2017)
Volume 155, Issue 3, Pages (October 2013)
Volume 18, Issue 12, Pages (December 2010)
Volume 16, Issue 2, Pages (August 2014)
HIV-1 Vpu Mediates HLA-C Downregulation
Volume 18, Issue 6, Pages (December 2015)
Volume 17, Issue 11, Pages (November 2009)
Volume 19, Issue 6, Pages (June 2016)
A Therapeutic Antibody for Cancer, Derived from Single Human B Cells
Volume 18, Issue 9, Pages (February 2017)
Volume 22, Issue 3, Pages e5 (September 2017)
Volume 43, Issue 6, Pages (December 2015)
Volume 19, Issue 5, Pages (May 2011)
Volume 16, Issue 3, Pages (September 2014)
Volume 21, Issue 13, Pages (December 2017)
Volume 1, Issue 2, Pages (April 2007)
Volume 161, Issue 7, Pages (June 2015)
Volume 14, Issue 1, Pages (January 2016)
Finding Leishmania: A Deadly Game of Hide-and-Seek
HIV-Host Interactions: Implications for Vaccine Design
Volume 21, Issue 6, Pages (June 2013)
Volume 13, Issue 12, Pages (December 2015)
Volume 19, Issue 5, Pages (May 2016)
Adam S. Dingens, Hugh K. Haddox, Julie Overbaugh, Jesse D. Bloom 
Volume 24, Issue 11, Pages (November 2016)
Volume 20, Issue 12, Pages (September 2017)
Volume 22, Issue 2, Pages (August 2017)
Volume 14, Issue 5, Pages (November 2013)
Volume 16, Issue 3, Pages (September 2014)
Volume 21, Issue 10, Pages (December 2017)
Volume 22, Issue 2, Pages (February 2005)
Double Trouble: HIV Latency and CTL Escape
Volume 24, Issue 5, Pages (May 2016)
Volume 7, Issue 2, Pages (February 1999)
Volume 23, Issue 3, Pages (April 2018)
Volume 4, Issue 6, Pages (December 2008)
Jinal N. Bhiman, Penny L. Moore  Immunity 
Volume 158, Issue 3, Pages (July 2014)
Recognizing Macrophage Activation and Host Defense
Volume 38, Issue 1, Pages (January 2013)
Volume 14, Issue 4, Pages (October 2013)
Volume 24, Issue 8, Pages (August 2016)
A Stable Prefusion Intermediate of the Alphavirus Fusion Protein Reveals Critical Features of Class II Membrane Fusion  Claudia Sánchez-San Martín, Hernando.
Bispecific Antibodies Against HIV
Volume 7, Issue 3, Pages (May 2014)
Volume 4, Issue 3, Pages (September 2008)
Volume 2, Issue 7, Pages (July 1994)
HIV Broadly Neutralizing Antibodies: Taking Good Care Of The 98%
Volume 25, Issue 6, Pages e5 (June 2019)
Volume 17, Issue 6, Pages (November 2016)
Volume 25, Issue 1, Pages e8 (January 2019)
Hitting HIV’s Harpoon Immunity
Volume 41, Issue 6, Pages (December 2014)
Volume 49, Issue 6, Pages e8 (December 2018)
Volume 24, Issue 4, Pages e3 (October 2018)
Presentation transcript:

Volume 18, Issue 3, Pages 354-362 (September 2015) Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses  M. Anthony Moody, Feng Gao, Thaddeus C. Gurley, Joshua D. Amos, Amit Kumar, Bhavna Hora, Dawn J. Marshall, John F. Whitesides, Shi-Mao Xia, Robert Parks, Krissey E. Lloyd, Kwan-Ki Hwang, Xiaozhi Lu, Mattia Bonsignori, Andrés Finzi, Nathan A. Vandergrift, S. Munir Alam, Guido Ferrari, Xiaoying Shen, Georgia D. Tomaras, Gift Kamanga, Myron S. Cohen, Noel E. Sam, Saidi Kapiga, Elin S. Gray, Nancy L. Tumba, Lynn Morris, Susan Zolla-Pazner, Miroslaw K. Gorny, John R. Mascola, Beatrice H. Hahn, George M. Shaw, Joseph G. Sodroski, Hua-Xin Liao, David C. Montefiori, Peter T. Hraber, Bette T. Korber, Barton F. Haynes  Cell Host & Microbe  Volume 18, Issue 3, Pages 354-362 (September 2015) DOI: 10.1016/j.chom.2015.08.006 Copyright © 2015 Elsevier Inc. Terms and Conditions

Cell Host & Microbe 2015 18, 354-362DOI: (10.1016/j.chom.2015.08.006) Copyright © 2015 Elsevier Inc. Terms and Conditions

Figure 1 Clonal Lineages Derived from CH0457 (A) The kite-shaped gate shows a diagonal of gp120ConC core+/+ memory B cells that were sorted as single cells. Antigen-specific cell frequency was similar in both samples; week 8 is shown. (B) IgG1 gp120 V3 mAbs (CH14, CH48) were not related to other isolated mAbs. Lineage CH13 had six IgG1 mAbs (VH1 ∼69/JH3; VK1 ∼39/JK4); mean heavy chain (HC) mutation frequency = 9.8%. Lineage CH27 had three mAbs: two IgA2 (CH27, CH28) and a IgG1 (CH44) (VH3 ∼66/JH2; VK3 ∼20/JK1); mean HC mutation frequency = 15.7%. Trees were plotted on the same scale. (C) Residues critical for lineage CH13 and lineage CH27 mAb binding (Tables S2 and S3) highlighted in the structure of gp120C.YU2 (CD4 light gray, gp120 light blue, mAb 17b not shown). Mapped residues are largely located within the CD4-gp120 contact surface. V1/V2 is not shown because it was absent in the crystal structure. (D) CH14 and CH48 binding to peptides reflective of multiple HIV-1 clades. Both bound V3 loop peptides (residues 301–325) across multiple clades; no binding was found for other epitopes. Cell Host & Microbe 2015 18, 354-362DOI: (10.1016/j.chom.2015.08.006) Copyright © 2015 Elsevier Inc. Terms and Conditions

Figure 2 Heterologous Neutralization by mAbs from CH0457 Neutralization of mAbs against tier 1 and tier 2 viruses from diverse clades shown in colored boxes (EC50). Control (HIVIG-C) and CH0457 serum from weeks 8 and 96 are shown; serum is shown as reciprocal ED50. Lineage CH13 mAbs and non-lineage mAbs (CH14, CH48) potently neutralized tier 1 viruses but only neutralized one tier 2 virus (C.246F_C1G). Lineage CH27 neutralized one tier 1 virus but 23/40 (58%) tier 2 viruses. CH0457 serum from weeks 8 and 96 neutralized all tier 1 viruses at > 1:20 and 37/40 (93%) and 31/40 (78%) of tier 2 viruses, respectively. Cell Host & Microbe 2015 18, 354-362DOI: (10.1016/j.chom.2015.08.006) Copyright © 2015 Elsevier Inc. Terms and Conditions

Figure 3 Heterologous Neutralization by mAbs from CH505 V3 mAbs DH151 and DH228 from CH505 tested against heterologous HIV isolates. Tier 1 isolates (2/4) were neutralized; 0/16 tier 2 isolates were neutralized. Cell Host & Microbe 2015 18, 354-362DOI: (10.1016/j.chom.2015.08.006) Copyright © 2015 Elsevier Inc. Terms and Conditions

Figure 4 Autologous Neutralization and Env Sequence Phylogenies (A–C) Neutralization heat map of autologous serum and mAbs shown. Each row in the neutralization panel (A) of 84 CH0457 pseudoviruses and phylogeny tree (B) is a distinct Env isolate spanning week 0 (enrollment; red) to week 96 after enrollment (purple). PBMC provirus sequences are gray. Autologous serum neutralization (reciprocal dilution) and isolated mAbs (μg/ml) are shown for (A) lineage CH13 mAbs (tier 1 CD4bs), lineage CH27 mAbs (tier 2 CD4bs), and CH14 and CH48 (tier 1 V3) and (C) CH505 mAbs DH151 and DH228 (tier 1 V3) and lineage CH103 (tier 2 CD4bs). (D) CH505 Env phylogeny spans transmission (week 0, red) through week 100 (purple). A high fraction of circulating viruses were sensitive to autologous mAbs. Cell Host & Microbe 2015 18, 354-362DOI: (10.1016/j.chom.2015.08.006) Copyright © 2015 Elsevier Inc. Terms and Conditions